Comparative Pharmacology
Head-to-head clinical analysis: BENICAR versus EDARBYCLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR versus EDARBYCLOR.
BENICAR vs EDARBYCLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination